---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057524"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:54:51.733747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tvardi Q1 net loss narrows to $6.8M; TTI-109 data due June, TTI-101 HCC data 2H 2026

## Summary
- Net loss of $6.8M ($0.73 per share) vs $9.6M ($3.72) in Q1 2025; R&D spend rose to $4.9M.
- Cash, cash equivalents and ST investments $25.0M at March 31, 2026; runway through Q4 2026.
- TTI-109 Phase 1 healthy volunteer topline data and development strategy expected June 2026.
- TTI-101 Phase 2 HCC topline data on track for 2H 2026; IPF fibrosis score reduction 9.4% vs 2.4% placebo.
- TTI-109 is a next-generation STAT3 prodrug designed for improved tolerability vs TTI-101.

## SEC filing metadata
- accession: 0001104659-26-057524
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/0001104659-26-057524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057524
- JSON: https://secwatch.observer/filing/0001104659-26-057524.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057524.txt

## Source-grounded claims
- claim_id: 7d4d3a9ab92a1d50d722836ce84e3f180ebff93d
  claim: Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $6.8 million, EPS $(0.73).
  evidence_excerpt: Net loss for the three months ended March 31, 2026, was $6.8 million, as compared to a net loss of $9.6 million for the comparable period in 2025. Basic and diluted net loss per share attributable to common shareholders for the three months ended March 31, 2026, were a net loss of $(0.73), compared to a net loss of $(3.72) for the comparable period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/0001104659-26-057524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.